登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Cell，11月9日，Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-11-18

  • Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques
    Timothy N. Hoang 13
    Maria Pino 13
    Arun K. Boddapati 13
    Raymond F. Schinazi 14
    Steven E. Bosinger 14
    Mirko Paiardini 14, 15

    Published:November 09, 2020DOI:https://doi.org/10.1016/j.cell.2020.11.007

    Summary
    SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type-I IFN antiviral responses and SARS-CoV-2-specific T-cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib treated animals had a rapid and remarkably potent suppression of lung macrophages production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.

  • 原文来源：https://www.cell.com/cell/fulltext/S0092-8674(20)31466-5
12浏览量
原文链接
相关报告

  • 《11月9日_Baricitinib可减轻感染SARS-CoV-2的恒河猴的相关症状》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-11-18
    • 埃默里大学的研究人员11月9日在期刊Cell上在线发表了题为“Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques”的文章。 文章称，SARS-CoV-2诱导的高细胞血症和炎症与COVID-19疾病的严重程度严重相关。Baricitinib（巴瑞克替尼）是一种临床批准的JAK1/2抑制剂，目前正在进行临床试验。研究人员调查了Baricitinib在SARS-CoV-2恒河猴猕猴模型中的免疫学和病毒学功效。使用Baricitinib不会减少从鼻腔、咽喉拭子、支气管肺泡灌洗和组织中检测到的病毒排出量。I型IFN抗病毒反应和SARS-CoV-2特异性T细胞反应在使用Baricitinib治疗和未使用Baricitinib治疗之间仍然保持相似。用Baricitinib治疗的动物表现出炎症减少、肺炎症细胞肺部浸润减少、NETosis活性降低以及肺部病理更加局限。重要的是，用Baricitinib治疗的动物对巨噬细胞产生的细胞因子、趋化因子以及中性粒细胞的招募具有迅速而显著的抑制作用。这些数据表明，Baricitinib可以治疗由SARS-CoV-2引起的一系列炎症，并表明了其潜在的免疫学机制。 原文链接：https://www.cell.com/cell/fulltext/S0092-8674(20)31466-5
    10浏览量
    原文链接

  • 《Cell，10月9日，Vascular Disease and Thrombosis in SARS-CoV-2 Infected Rhesus Macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-10-15
    • Vascular Disease and Thrombosis in SARS-CoV-2 Infected Rhesus Macaques Malika Aid Kathleen Busman-Sahay Samuel J. Vidal Amanda J. Martinot Jacob D. Estes Dan H. Barouch Show all authors Published:October 09, 2020DOI:https://doi.org/10.1016/j.cell.2020.10.005 Abstract The COVID-19 pandemic has led to extensive morbidity and mortality throughout the world. Clinical features that drive SARS-CoV-2 pathogenesis in humans include inflammation and thrombosis, but the mechanistic details underlying these processes remain to be determined. In this study, we demonstrate endothelial disruption and vascular thrombosis in histopathologic sections of lungs from both humans and rhesus macaques infected with SARS-CoV-2. To define key molecular pathways associated with SARS-CoV-2 pathogenesis in macaques, we performed transcriptomic analyses of bronchoalveolar lavage (BAL) and peripheral blood and proteomic analyses of serum. We observed macrophage infiltrates in lung and upregulation of macrophage, complement, platelet activation, thrombosis, and proinflammatory markers, including C-reactive protein, MX1, IL-6, IL-1, IL-8, TNFα, and NF-κB. These results suggest a model in which critical interactions between inflammatory and thrombosis pathways lead to SARS-CoV-2 induced vascular disease. Our findings suggest potential therapeutic targets for COVID-19.
    118浏览量
    原文链接